Establishing an Environment for Timely and High-Quality Clinical Trials
Innovative Treatment Opportunities for Patients with Chronic, Rare Diseases, and Cancer
AstraZeneca Korea announced on May 22 that it has signed a partnership with Severance Hospital to strengthen collaboration on clinical trials.
Jeon Sehwan, CEO of AstraZeneca Korea (right), and Lee Kangyoung, Director of Severance Hospital (left), are taking a commemorative photo after signing a partnership to strengthen clinical trial collaboration on the 21st at Severance Hospital in Seodaemun-gu, Seoul. AstraZeneca Korea
According to AstraZeneca Korea, the agreement aims to create an environment that enables high-quality clinical trials to be conducted efficiently and in a timely manner, while also providing innovative treatment opportunities to domestic patients suffering from chronic diseases, rare diseases, and cancer.
Under the agreement, AstraZeneca Korea will share its clinical development plans for both existing and future development portfolios with Severance Hospital. The company also plans to design optimized implementation strategies to ensure the smooth operation of clinical trials. In particular, by conducting high-difficulty clinical trials for new drugs such as CAR-T (chimeric antigen receptor T-cell) therapies more efficiently in Korea, it is expected that patients with limited treatment options will gain earlier access to innovative therapies, thereby improving patient access to treatment.
Jeon Sehwan, CEO of AstraZeneca Korea, stated, "AstraZeneca Korea is committed to building a patient-centered healthcare ecosystem based on our corporate value of 'putting patients first.' Our partnership with Severance Hospital is part of this effort, and we will continue to work with the domestic medical community to deliver innovative treatment solutions to patients more quickly."
He added, "Korea has long been recognized as a key hub for global clinical trials, but as competition to attract clinical trials has intensified recently, investment is inevitably focused on countries that provide reimbursement for innovative new drugs. Korea needs to consider how it can continue to maintain its global competitiveness in this area."
Lee Kangyoung, Director of Severance Hospital, said, "I am very pleased that the excellent researchers and medical infrastructure at Severance Hospital, combined with AstraZeneca Korea's global clinical expertise, will provide more domestic patients with early access to innovative treatments. The strategic partnership with AstraZeneca Korea will be an important milestone in advancing the domestic clinical trial environment and improving access to innovative therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
